Company / R&D Expense
PAVmed Inc. R&D Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$5.9M
FY2025
5-year range
$5.9M / $25.3M
FY2021-FY2025
Trend
-58.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $25M to $6M over the past 2 years.
Based on SEC 10-K filings.
$6M in FY2025 with a 3-year CAGR of -33.1%.
Declined from $25M to $6M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -33.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -33.1%, indicating a declining trend.
- In FY2025, r&d expense decreased 58.4% year-over-year.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.9M | -58.4% |
| FY2024 | $14.3M | -43.7% |
| FY2023 | $25.3M | +27.7% |
| FY2022 | $19.8M | +81.0% |
| FY2021 | $11.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026